![brand logo](/content/dam/AAFP/images/logos_internal/afp-masthead-2021.png)
Am Fam Physician. 2023;107(6):online
Author disclosure: No relevant financial relationships.
![](/content/dam/brand/aafp/pubs/afp/MBTN-600x394.gif)
Details for This Review
Study Population: 8,805 patients with proven or suspected acute bacterial conjunctivitis
Efficacy End Points: Clinical effectiveness (i.e., clinical cure); resolution of at least two of the following three signs after a course of antibiotic therapy: bulbar conjunctival injection, palpebral conjunctival injection, and any purulent epiphora
Harm End Points: Antibiotic-associated ocular or systemic complications
![](/content/dam/brand/aafp/pubs/afp/issues/2023/0600/p581A-ut1.gif)
Benefits | Harms |
---|---|
1 in 7 was helped (clinical cure after a course of antibiotics therapy) | 1 in 32 was harmed (experienced ocular adverse effects compared with placebo) |
Subscribe
From $165- Immediate, unlimited access to all AFP content
- More than 130 CME credits/year
- AAFP app access
- Print delivery available
Issue Access
$59.95- Immediate, unlimited access to this issue's content
- CME credits
- AAFP app access
- Print delivery available